Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Emotional change-associated T cell mobilization at the early stage of a mouse model of multiple sclerosis.

Piras G, Rattazzi L, McDermott A, Deacon R, D'Acquisto F.

Front Immunol. 2013 Nov 21;4:400. doi: 10.3389/fimmu.2013.00400. eCollection 2013.

2.

The double-edged sword of autoimmunity: lessons from multiple sclerosis.

Hestvik AL.

Toxins (Basel). 2010 Apr;2(4):856-77. doi: 10.3390/toxins2040856. Epub 2010 Apr 22. Review.

3.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
4.
5.

Differentiation of multiple sclerosis subtypes: implications for treatment.

Bitsch A, Brück W.

CNS Drugs. 2002;16(6):405-18. Review.

PMID:
12027786
6.

Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment.

De Santi L, Polimeni G, Cuzzocrea S, Esposito E, Sessa E, Annunziata P, Bramanti P.

Curr Med Chem. 2011;18(12):1775-84. Review.

PMID:
21466473
7.

Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis.

van Zwam M, Huizinga R, Heijmans N, van Meurs M, Wierenga-Wolf AF, Melief MJ, Hintzen RQ, 't Hart BA, Amor S, Boven LA, Laman JD.

J Pathol. 2009 Mar;217(4):543-51. doi: 10.1002/path.2476.

PMID:
19023878
8.

Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis.

Tischner D, Weishaupt A, van den Brandt J, Müller N, Beyersdorf N, Ip CW, Toyka KV, Hünig T, Gold R, Kerkau T, Reichardt HM.

Brain. 2006 Oct;129(Pt 10):2635-47. Epub 2006 Aug 18.

9.

Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.

Berthelot L, Miqueu P, Pettré S, Guillet M, Moynard J, Wiertlewski S, Lefrère F, Brouard S, Soulillou JP, Laplaud DA.

Clin Immunol. 2010 Apr;135(1):33-42. doi: 10.1016/j.clim.2009.12.006. Epub 2010 Feb 8.

PMID:
20116333
10.
11.
12.

Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.

Sonobe Y, Jin S, Wang J, Kawanokuchi J, Takeuchi H, Mizuno T, Suzumura A.

Tohoku J Exp Med. 2007 Dec;213(4):329-39.

13.

Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity.

Patas K, Engler JB, Friese MA, Gold SM.

J Reprod Immunol. 2013 Mar;97(1):140-6. doi: 10.1016/j.jri.2012.10.005. Review.

PMID:
23432880
14.

The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation.

Zozulya AL, Wiendl H.

Hum Immunol. 2008 Nov;69(11):797-804. doi: 10.1016/j.humimm.2008.07.014. Epub 2008 Aug 22. Review.

PMID:
18723060
15.

Vaccines for multiple sclerosis: progress to date.

Correale J, Farez M, Gilmore W.

CNS Drugs. 2008;22(3):175-98. Review.

PMID:
18278975
17.

Extracorporeal photophoresis: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1.

18.

Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.

Putheti P, Pettersson A, Soderstrom M, Link H, Huang YM.

J Clin Immunol. 2004 Mar;24(2):155-61.

PMID:
15024182
19.

Inflammation modulates anxiety in an animal model of multiple sclerosis.

Peruga I, Hartwig S, Thöne J, Hovemann B, Gold R, Juckel G, Linker RA.

Behav Brain Res. 2011 Jun 20;220(1):20-9. doi: 10.1016/j.bbr.2011.01.018. Epub 2011 Jan 19.

PMID:
21255614
20.

Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways.

Weller RO, Engelhardt B, Phillips MJ.

Brain Pathol. 1996 Jul;6(3):275-88. Review.

PMID:
8864284
Items per page

Supplemental Content

Write to the Help Desk